Prohibitin (PHB) is a cell cycle regulatory protein, known to repress E2F1-mediated gene activation via recruitment of transcriptional regulatory factors such as retinoblastoma and histone deacetylase 1 (HDAC1). We previously identified PHB as a target protein of androgen signaling in prostate cancer cells and showed that downregulation of PHB is required for androgen-induced cell cycle entry in these cells. We now present evidence that PHB, which has 54% homology at the protein level to the oestrogen receptor corepressor REA (repressor of oestrogen receptor activity), can repress androgen receptor (AR)-mediated transcription and androgen-dependent cell growth. Depletion of endogenous PHB resulted in an increase in expression of the androgen-regulated prostatespecific antigen gene. The repression appears to be specific to androgen and closely related receptors, as it is also evident for the glucocorticoid and progesterone, but not oestrogen, receptors. In spite of interaction of PHB with HDAC1, HDAC activity is not required for this repression. Although AR and PHB could be co-immunoprecipitated, no direct interaction was detectable, suggesting that PHB forms part of a repressive complex with the AR. Competition with the co-activator SRC1 further suggests that formation of a complex with AR, PHB and other cofactors is the mechanism by which repression is achieved. It appears then that repression of AR activity is one mechanism by which PHB inhibits androgendependent growth of prostate cells. Further, this study implies that the AR itself could, by mediating downregulation of a corepressor, be involved in the progression of prostate tumours to the hormone refractory stage.
Introduction
Prohibitin (PHB) is a highly conserved 32 kDa protein with homologues in all animal species, yeast and plants. Upon discovery, it was suspected to be a tumour suppressor protein (McClung et al., 1989; Nuell et al., 1991) , and was found to be located in the inner membrane of the mitochondria, where it acts as a chaperone in a complex with the structurally similar protein BaP37/REA (repressor of oestrogen receptor activity) (Coates et al., 1997; Steglich et al., 1999) . More recently, PHB has been found in the nucleus of several cell lines, such as ovarian granulosa, breast epithelial and prostate epithelial cells (Thompson et al., 2001; Wang et al., 2002; Fusaro et al., 2003; Gamble et al., 2004) . In these cells, it appears that PHB has a second function, whereby it interacts with proteins such as nuclear corepressor (NCoR), histone deacetylase 1 (HDAC1) and retinoblastoma (Rb) to repress activation of genes regulated by the E2F family of transcription factors (Wang et al., 1999 . This repression of E2F1 activity has been shown to be important in the protection of Ramos B cells from camptothecin-induced apoptosis . Further, recruitment of PHB and BRG1/BRM has been shown to inhibit E2F activation and cause growth arrest in breast cancer cells treated with the antioestrogen tamoxifen. This recruitment of PHB and repression of E2F-mediated transcription was induced via the c-Jun N-terminal kinase 1 pathway (Wang et al., 2004b) . The current data therefore appear to show PHB as part of a repressive complex of proteins that is vital to growth regulation in hormone-sensitive cells. The E2F and HDAC1 binding region of PHB has subsequently been mapped to a coiled-coil domain of the protein, which caused apoptosis when transfected into several cell lines . PHB has also been shown to play a role in the mitogen-activated protein kinase pathway, allowing activation of the Raf-MEK-ERK pathway by Ras and affecting adherens junction formation (Rajalingam et al., 2005) .
We previously identified PHB as being downregulated in the LNCaP prostate cancer cell line following growth stimulation with the androgen dihydrotestosterone (DHT). We demonstrated that reduction of PHB levels in stimulated LNCaP cells was necessary for cell cycle progression, and that reduction of PHB levels by RNA interference partially mimicked DHT treatment by causing a small increase in cells entering the S phase . This suggests that PHB has a role in the control of androgen-stimulated cell division, which is mediated by the androgen receptor (AR), a ligand-activated transcription factor. Binding of androgen to the AR causes it to increase transcription of genes under the control of androgen response elements (AREs). To achieve this, the ARE-bound AR recruits co-activator proteins that promote transcription by altering the topology of chromatin to allow access of the basal transcriptional machinery, or by stabilizing the pre-initiation complex (Bevan and Parker, 1999; Belandia and Parker, 2003) . Conversely, corepressor proteins have also been identified that are required for repression of basal transcription by some nuclear receptors in the absence of ligand (Hu and Lazar, 2000) . These recruit proteins with HDAC activity, promoting heterochromatin formation thus restricting access of transcription factors and the pre-initiation complex. Although unliganded steroid receptors appear not to recruit corepressors, several groups have found that the corepressors NCoR and silencing mediator of retinoid and thyroid hormone receptor (SMRT) associate with oestrogen and progesterone receptors (ERs and PRs) and AR in the presence of antagonists (Jackson et al., 1997; Smith et al., 1997; Wagner et al., 1998; Zhang et al., 1998; Berrevoets et al., 2004) . Therefore, corepressors may be required for DNA-bound nuclear receptors to inhibit transcriptional activity.
As prostate tumours are initially dependent on androgens for growth, current therapy for prostate cancer includes the use of antiandrogens that bind to the AR but inhibit transcription of target genes. Corepressors could be required for such inhibition of AR activity by antiandrogens. In support of this, NCoR was recruited to the androgen-responsive prostate-specific antigen (PSA) promoter in the presence of antiandrogen in a prostate cancer cell line (Masiello et al., 2002) and was also found to enhance the antagonistic effects of partial AR agonists . Given that PHB shows a high degree of homology to the ER corepressor BaP37/REA (Montano et al., 1999; DelageMourroux et al., 2000) , is known to bind HDAC1 and NCoR , and has a negative effect on androgen stimulated growth in LNCaP cells , it is possible that PHB could be a corepressor of the AR. Here, we show that PHB indeed has a repressive effect on AR activity but appears not to interact directly with AR, suggesting that PHB forms part of a repressive complex that includes the AR.
Results

PHB is partially nuclear in AR-positive cells
We previously demonstrated nuclear localization of PHB in the LNCaP prostate cancer cell line, which is AR-positive and androgen sensitive. Fractionation into the nuclear and cytoplasmic compartments was carried out on this and further prostate cancer cell lines PC3 (AR-negative) and PC3wtAR (PC3 stably transfected with AR (Whitaker et al., 2004) ); and other cell lines known to be AR-positive (the breast cancer cell line MCF7) or -negative (COS-1), and the resultant protein extracts blotted for PHB. Strong cytoplasmic expression was seen in all cell lines tested, irrespective of AR status, confirming that the mitochondrial presence of PHB is ubiquitous (Figure 1a) . Further, all cell lines demonstrated positive nuclear staining for PHB, this was strongest in the AR-positive MCF7 cells, but low levels of nuclear PHB were also evident in the AR-negative cells. Control blotting for a known mitochondrial protein, manganese superoxide dismutase (MnSOD) (Ho and Crapo, 1988) , demonstrated that this was not due to cross-contamination from the cytoplasmic fraction. These results were corroborated by confocal microscopy showing PHB is present in nuclear speckles in all cell lines studied, to varying degrees ( Figure 1b) . Again high levels of cytoplasmic/mitochondrial staining were visible in all lines tested.
PHB inhibits AR activity
The PHB protein shares high homology to BAP37, also termed REA (repressor of oestrogen receptor activity) as it was found to inhibit oestrogen-induced activity of the ER and to potentiate antioestrogen action, although it did not inhibit activity of the AR (Montano et al., 1999) . Hence, we investigated whether PHB has an effect on AR activity. Overexpression of PHB in COS-1 cells cotransfected with AR expression vector, androgenresponsive reporter and increasing amounts of PHB expression vector showed that PHB inhibits or represses ligand-dependent AR activity by up to 83% (Figure 2a ). This was evident on all three different reporter vectors tested, thus was not a promoter-specific effect. In order to determine whether this effect is dependent on cell type, we repeated the assay on two promoters in PC3 cells ( Figure 2b ) and MCF7 cells (which express endogenous AR, Figure 2c ). In both of these cell lines, PHB again acted as a repressor of AR activity, reducing activity to a similar level as seen in COS cells. Hence, PHB is able to inhibit activity of both overexpressed and endogenous AR in a manner that is not cell typeor promoter-specific.
PHB represses activity of AR and closely related receptors but not ER The AR is a member of the steroid receptor subfamily also containing the glucocorticoid receptor (GR), PR and mineralocorticoid receptor, and it binds to the same response elements as these receptors. We investigated whether PHB could repress activity of GR and PR on a common response element (TAT-GRE) in COS-1 cells. We found that ligand-dependent activity of these receptors was also inhibited by PHB (Figure 3a and b) although to a slightly lesser extent than that of AR. However, the activity of the ER, which binds to different response elements, was not affected by overexpression of PHB when measured on the oestrogenresponsive pS2 promoter (Figure 3c ). Hence, PHB appears to be a specific repressor of the GR-like steroid receptors. This is in contrast to REA, which repressed activity of the ER but not the AR or PR (Montano et al., 1999) .
PHB (endogenous and overexpressed) represses androgen-dependent endogenous gene expression and growth in prostate cancer cells To determine whether endogenous levels of PHB are able to inhibit endogenous AR activity, we used small interfering RNA (siRNA) to deplete PHB levels in LNCaP cells and measured expression of the androgenregulated PSA gene. PSA levels in the media were increased by approximately 50% after knockdown of PHB, demonstrating that, in the absence of any overexpressed protein, normal levels of PHB can inhibit androgen-dependent AR activity (Figure 4a) .
To assess the effects of stably transfected PHB on expression of an endogenous androgen-responsive gene and on androgen-dependent growth, LNCaP cells were stably transfected with a tetracycline-inducible PHB expression vector. Addition of tetracycline (doxycycline) to these cells increased PHB RNA and protein levels (Figure 4b and c) . Androgen-induced expression of the PSA gene was reduced by around 30% in the presence of 1 mM doxycycline, that is, increased PHB levels ( Figure 4d ). The androgen-dependent growth of these cells was also investigated. Two different doxycycline concentrations were used, neither of which were toxic or altered cell growth in the absence of androgens (under which conditions these cells are growth-quiescent, Figure 4e ). However, the growth of these cells induced by 1 nM mibolerone (MB) was significantly reduced by the addition of doxycycline, hence the induction of PHB expression (Figure 4f ).
Interaction between PHB and the AR may be indirect As PHB appears to act as a corepressor of the AR, and corepressors are usually directly recruited to nuclear receptors, we investigated whether PHB could interact directly with AR. In co-immunoprecipitation experiments, interaction between overexpressed PHB and AR was observed (Figure 5a, upper panel) . Interaction between the endogenous proteins was also evident but was very weak (Figure 5a , lower panel). Further, no interaction was seen in a pulldown assay between PHB fused to glutathione-S-transferase and endogenous AR in PC3wtAR cell extracts or in vitro translated AR protein, or in a yeast 2-hybrid assay between full-length PHB and full-length AR or fragments of AR ( Supplementary Figures 1 and 2 ). This suggests that the interaction seen by immunoprecipitation may be indirect.
Previously, the ER-interacting region of REA was mapped to amino acids 175-198 (underlined in Figure 5b ) (Delage-Mourroux et al., 2000) . This region shows high homology between REA and PHB, and contains an FxxIL motif that is similar to motifs recently shown to have high affinity for the AR (Dubbink et al., 2004; Hur et al., 2004) . We therefore mutated this motif to determine whether it is required for in vivo repression of AR function by PHB. Deletion of the five amino acids FGLIL (161-165), or mutation to AGLIL or AGLAA, had little effect on the ability of PHB to repress AR activity (Figure 5c ), although deletion of amino acids 161-165 did reduce the maximum repression. Therefore, this region is not essential for interaction with AR or for repression by PHB in vivo.
Mechanisms of PHB-mediated repression
In the absence of a demonstrable direct PHB:AR interaction, we investigated mechanisms by which PHB may be repressing AR-dependent activity. Previously, Wang et al. (1999 Wang et al. ( , 2002 showed that PHB represses E2F activity via recruitment of HDAC1 and NCoR and that this repression also requires interaction of PHB with pRb. Recruitment of such corepressor proteins is a possible mechanism by which PHB is repressing AR activity; hence, we examined whether PHB interacts with these proteins in a hormone-sensitive cell line (MCF7). We confirmed that endogenous PHB binds to endogenous HDAC1 and pRb ( Figure 6a ) and also that AR interacts with Rb. Further, confocal microscopy revealed that HDAC1 localizes to speckles in the nucleus similar to those containing PHB, and some colocalization of the two proteins was evident, supporting a possible functional interaction (data not shown). HDACs are believed to repress transcription by deacetylating histones at the promoter, resulting in an inaccessible chromatin structure. We used an inhibitor of deacetylase activity, trichostatin A (TSA), to determine whether such deacetylation was required for repression of AR activity by PHB. Treating cells with 100 nM TSA resulted in an overall increase in activity (approximately 16-fold, not shown), indicating that this concentration of TSA is able to relax chromatin by inhibiting histone deacetylation, and this was supported by an increase in acetylation of histone H3 in treated cells (Supplementary Figure 3) . However, PHB was still able to repress this activity to the same extent as in the absence of TSA (Figure 6b ). Similar results were seen when cells were treated with 10 and 500 nM TSA, and with four other HDAC inhibitors: valproic acid (5 mM), suberoylanilide hydroxamic acid (1 mM), nicotinamide (5 mM) and sodium butyrate (5 mM) (data not shown). This indicates that, although PHB interacts with HDAC1, repression of AR activity is via a deacetylase-independent mechanism. One possible mechanism of repression is that PHB prevents recruitment of coactivators to AR. Overexpression of the co-activator SRC1e increased ligand-dependent AR activity by approximately fivefold, and co-expression of PHB reduced the SRC1-enhanced activity in a dose-dependent manner (Figure 6c) . Conversely, when AR activity was repressed by expression of 50 ng PHB, co-expression of SRC1e reversed this repression, again in a dosedependent manner (Figure 6d ). Hence, there appears to be competition at the functional level between PHB and this co-activator. We next investigated the effect of PHB overexpression on the ability of AR to bind ligand. In COS-1 cells transfected with expression vectors for AR and PHB, increasing levels of PHB resulted in an increase in dissociation of ligand from the AR (Figure 6e ).
Discussion
The inhibitory role of PHB in cell cycle regulation, and its ability to repress E2F1-mediated transcription via interaction with proteins such as Rb, HDAC1 and NCoR (Wang et al., 1999 , suggest that it forms part of a transcriptionally repressive complex, which may also affect other response elements and growth response pathways. Our discovery that PHB is downregulated in the LNCaP cell line following androgen stimulation, coupled with the observation that PHB was capable of inhibiting androgen-stimulated cell growth in these cells, suggested a major role for PHB in regulating the androgen-stimulated growth response . A protein with a regulatory role in transcription would most likely be located in the cell nuclei, where it could directly repress transcription from target genes. Early reports that PHB was located to the mitochondrial inner membrane have since been joined by several reports that PHB is also present in the nucleus of several cell types (Coates et al., 1997; Thompson et al., 2001; Wang et al., 2002; Gamble et al., 2004) . Our confocal microscopy results show a speckled appearance of PHB in the nucleus of several cell lines, supporting a nuclear role for PHB. Cell fractionation data demonstrated this nuclear presence clearly in steroid hormonesensitive cell lines as well as the PC3 line, which is androgen independent but derived from a metastatic prostate tumour, hence cells which were originally steroid sensitive. Relative nuclear PHB levels were highest in the highly steroid-responsive MCF7 line and lowest in COS-1 cells, which are completely steroid insensitive. It is possible therefore that the nuclear presence or role of PHB is related to steroid responsiveness. Other groups have demonstrated the presence of nuclear PHB in steroid hormone-sensitive ovarian granulosa and breast cancer cell lines (Thompson et al., 2001; Wang et al., 2002) .
We observed repression of transcription from several AREs by PHB overexpression and showed that it can also repress androgen-dependent transcription of the endogenous PSA gene. That this is likely to be a physiologically relevant phenomenon is supported by the observation that depleting endogenous PHB by siRNA resulted in an increase in androgen-dependent gene transcription. To our knowledge, this is the first report of an AR corepressor that is downregulated by androgens. A decrease in corepressor proteins has been postulated as a possible driving force behind the progression of hormone-dependent tumours to the hormone-refractory stage (Lavinsky et al., 1998) . This study indicates that the AR itself could be involved in downregulation of corepressors, thus increasing its own activity in tumours. The observed direct effect on the androgen-responsive pathway goes some way to explaining the ability of PHB to block androgenresponsive growth stimulation, as shown previously in transiently transfected cells and in this study using stably transfected, conditionally expressing cells. The specificity of this repression of responsive genes, which appears to be confined to steroid receptors in the GR-like subfamily, demonstrates that there may be a specific regulatory system for these receptors distinct from that of ER. In contrast, the repression of ER activity by REA was found to apply specifically to this receptor, and no repression of AR by REA was observed (Montano et al., 1999) . It is therefore possible that REA and PHB, although joined in a functional complex in the mitochondria (Nijtmans et al., 2000) , fulfil separate but parallel functions in the nucleus, with PHB regulating transcription by receptors in the GR-like subfamily, whereas REA exerts similar effects on ER.
Proteins that repress transcription from hormone response elements generally form multi-protein complexes on the response element that contain the receptor (Shang et al., 2002) . Although some interaction between PHB and AR was demonstrable by co-immunoprecipitation, attempts made to show direct interaction between the two proteins using various methods were unsuccessful, indicating that a complex exists containing both, but possibly without direct interaction between AR and PHB. PHB is known to interact with NCoR, a known corepressor of AR (Cheng et al., 2002) , as well as several proteins that form part of repressive complexes, including Brm, Brg and HDAC1 (Wang et al., , 2004b . Our co-immunoprecipitation results confirmed that PHB interacts directly with HDAC1. HDACmediated remodeling of chromatin is a well-documented mechanism of transcriptional repression in such complexes, so it was surprising that HDAC inhibitors did not reverse PHB-mediated transcriptional repression. It seems that, despite this interaction, HDAC-mediated remodeling of chromatin is not the method by which PHB represses AR-mediated transcription. In addition to its interaction with PHB, we and others have shown that Rb interacts with AR (Yeh et al., 1998 ), so it is therefore possible that a complex of Rb, PHB and AR forms which may have a repressive effect on AR activity. Rb is generally reported to be a co-activator of AR; however, it has also been shown to reduce the activation of AR by the protein pp32 indicating that Rb does have a repressive role in AR activity in certain contexts (Adegbola and Pasternack, 2005) . Also, the functional competition we observed between the coactivator SRC1e and PHB suggests that relative levels of PHB and co-activators may determine the formation of repressive or active transcriptional complexes involving AR, leading to increased or decreased transcription from genes with AREs. High levels of PHB were found to increase the rate of ligand displacement from AR. This could be due to inhibition of the N/C-terminal interaction, which decreases the ligand off-rate (Zhou et al., 1995) -interference with this interaction is one mechanism by which known corepressors inhibit AR activity (Wang et al., 2004a; Burd et al., 2005) . Dubbink et al. (2004) used variants of FxxLF motifs to show that interaction of AR with cofactors influenced the release of ligand from the receptor. It is possible that PHB at high concentrations may displace co-activators from the liganded AR complex and cause release of the ligand. Alternatively, it may be that PHB sequesters coactivators from active complexes, disrupting the complex and thereby promoting ligand dissociation. Overall, these results suggest that PHB is a component of a repressive protein complex recruited to ARE-containing promoters or enhancers, to repress transcription until growth is stimulated by liganded receptor, possibly by displacement of the complex, or by substitution of repressive components of the complex with co-activator proteins such as SRC1. Studies using chromatin IP have demonstrated the cyclical formation of receptor-containing complexes on steroid response elements during transcription, with members of the complex joining and leaving at specified points in the cycle (Metivier et al., 2003) . Therefore, it may be that a complex containing both PHB and AR regulates levels of transcription from genes with AREs at different concentrations of circulating androgen.
In conclusion, we have shown that PHB negatively affects the transcriptional activity of the AR and other closely related receptors, and repression of AR activity appears to be a mechanism by which PHB inhibits androgen-dependent growth of prostate cells. This repression is likely to be via formation of a complex of proteins and although HDAC1 interacts with PHB, HDAC remodeling of chromatin does not appear to be the method of repression. The formation of complexes containing PHB, AR and other cofactors such as Rb, in competition with co-activator complexes, does appear to play a role in repression. We therefore propose that downregulation of PHB following androgen stimulation is a necessary event, which reduces the levels of inhibitory complex and therefore allows increased transcription from the androgen-responsive genes, by which androgen-stimulated cell cycle entry is attained. Immunoprecipitates were separated on SDS-PAGE gels and immunoblotted for PHB, giving a band at 32 kDa, or AR (110 kDa). (b) COS-1 cells were co-transfected with pSVAR, TAT-GRE-luciferase and increasing amounts of pSG5-PHB. Cells were then treated for 24 h with 10 nM MB and 100 nM TSA (dotted line) or vehicle (DMSO, solid line). Luciferase activity was assayed and corrected for b-galactosidase activity. Activity in the absence of PHB was set at 100% for each condition and other values expressed relative to this. Data shown are mean7s.e. of three independent experiments performed in duplicate. (c, d) COS-1 cells were co-transfected with pSVAR, TAT-GRE-luciferase and either 200 ng of pSG5-SRC1 with increasing amounts of pSG5-PHB (c) or 50 ng of pSG5-PHB with increasing amounts of pSG5-SRC1e (d). Cells were then treated with 10 nM MB for 24 h; luciferase activity was assayed and corrected for b-galactosidase activity. Activity in the absence of SRC1e or PHB was set at 100% and other values expressed relative to this. Data shown are mean7s.e. of three independent experiments performed in duplicate. (e) COS-1 cells were transfected with expression vectors for AR and PHB. Cells were incubated with 5 nM 3 H-MB for 2 h at 371C followed by a chase of 2 mM unlabelled MB for different time periods. Cells were washed, lysed and 3 H-MB in the lysate measured by scintillation counting. Data are given as a natural logarithmic (ln) ratio of 3 H-MB bound (B) and that bound at 0 min (Bo). TSA ¼ trichostatin A.
Materials and methods
Cell culture COS-1 and MCF7 cells were maintained at 371C, 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) medium (Sigma-Aldrich, Dorsett, UK) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 5% foetal bovine serum. PC3 and LNCaP cells were maintained at 371C, 5% CO 2 in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma) supplemented as above, with the addition of 4 mg/ml Geneticin (Life Technologies, Strathclyde, UK) for PC3wtAR cells. Twenty-four hours before exposure to androgen or ethanol, media were replaced with phenol red-free DMEM or RPMI medium as appropriate, supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 5% charcoal stripped foetal bovine serum.
Nuclear localization and Western blotting
Following 16 h treatment with 10 nM of the synthetic DHT analogue MB (DuPont NEN), or an equivalent volume of ethanol, cells were washed twice in phosphate-buffered saline (PBS) before being separated into nuclear and cytoplasmic fractions using the NE-PER kit (Pierce Biotechnology, Perbio Science Ltd., Northumberland, UK) according to the manufacturer's guidelines. Each fraction was mixed with an equal amount of sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer and 40 ml of each fraction was loaded onto a 10% SDS polyacrylamide gel and separated by electrophoresis for approximately 2 h at 200 V. Proteins were then transferred onto a nitrocellulose membrane using a semi-dry blotting apparatus (Nova Blot, GE Healthcare, Amersham, UK). Membrane blocking was carried out overnight in PBS containing 5% non-fat milk powder before incubation with primary antibodies for 1 h at 41C. Antibodies used were mouse anti-human PHB primary antibody (Neomarkers, Stratech Scientific Ltd., Cambs, UK) diluted 1 in 2000, goat anti-human MnSOD antibody (Abcam, Cambridge, UK) diluted 1:1000 and mouse anti-human b-actin antibody (Abcam) diluted 1:3000. After subsequent membrane washing, detection was carried out using the horseradish peroxidase conjugated anti-mouse or anti-rabbit IgG secondary antibody diluted 1 in 1000 (Dako UK Ltd., Cambs, UK) and incubated for 1 h at 41C. Following further washes proteins were visualized using the enhanced chemiluminescence detection system as per the manufacturer's protocol.
Confocal microscopy
Cells were grown on sterile glass coverslips in 24-well plates to 30% confluence in RPMI media before being washed three times in PBS and fixed in methanol at À201C for 10 min. Coverslips were washed a further three times in PBS and treated with 10% whole goat serum (Dako Cytomation) for thirty minutes. Goat anti-human PHB antibody was applied in 10% whole goat serum for 1 h and coverslips washed three times in PBS. Ten per cent whole goat serum was applied to the coverslips for a further 15 min before incubating with either a fluorescein isothiocyanate isomer I (FITC) conjugated secondary antibody (Sigma) in the dark for 1 h. Cells were washed five times in PBS, mounted on glass slides with Vectorshield containing dapi (Vector Laboratories Inc.) and visualized on a Zeiss Meta 512 confocal microscope.
Mutation of the FxxIL motif in PHB
The motif FGLIL, amino acids 161-165 of the PHB protein, was mutated to AGLIL, AGLAA or deleted from the PHB coding sequence, by site directed mutagenesis using the QuikChange II site-directed mutagenesis kit (Stratagene Ltd., Stratech Scientific Ltd., Cambs, UK) as per manufacturer's protocol. polymerase chain reaction (PCR) primer pairs used were as follows: deletion primers, 5 0 -cgagccgcc acctccttgacacatctga-3 0 and 5 0 -tcagatgtgtcaaggaggtggcggctcg-3 0 ; AGLIL, 5 0 -gagccgccaccgctgggctcatcctgg-3 0 and 5 0 -ccaggatgagc ccggcggtggcggctcgc-3 0 ; AGLAA, 5 0 -gagccgccaccgctgggctcgccgc ggatgacgtgtccttg-3 0 and 5 0 -caaggacacgtcatccgcggcgagcccggcggt ggcggc-3 0 . These oligonucleotides were used to generate mutant variants of the PSG5-PHB expression vector described previously . Mutations were verified by sequencing.
Reporter and ligand binding assays
The following plasmids have been previously described: pSG5-SRC1e (Kalkhoven et al., 1998) , pSVAR (Brinkmann et al., 1989) , TAT-GRE-E1B-LUC, MMTV-LUC and probasin-LUC (Verrijdt et al., 2000) , pSG5-PHB , HEGO (Tora et al., 1989) , PSG5-PRB and pSG5-GR (Kalkhoven et al., 1994) .
For experiments to determine the effect of PHB overexpression COS-1, MCF7 and PC3 cells were cultured in phenol red-free medium as stated above in 24-well plates for 24 h before transfection. Cells were transfected using a modified calcium phosphate method (Chen and Okayama, 1987) with each well receiving 0.5 mg of the reporter as stated, 25 ng BOS-b-galactosidase, 50-200 ng of pSG5-PHB and for COS-1 and PC3 cells 25 ng of receptor expression plasmid (pSVAR, pSG5-PR-B, pSG5-GR or HEGO). For SRC1/PHB competition experiments and to study the effect of PHB mutants, COS-1 cells were transfected with 25 ng of pSVAR, 0.5 mg of TAT-GRE-E1B-LUC, 25 ng of BOS-b-galactosidase and pSG5-PHB (wild-type or mutant) and/or pSG5-SRC1e as stated. In all cases, empty vector was used to normalize DNA amounts. After transfection, cells were washed and incubated for 24 h in medium containing vehicle (ethanol) or 10 À8 M of the appropriate hormone, either MB, the glucocorticoid dexamethasone, progesterone or 17b-estradiol (Sigma-Aldrich, Dorsett, UK). Luciferase activity was assayed using the Luclite assay kit (Perkin-Elmer, Beaconsfield, UK) and normalized against b-galactosidase activity, assayed using the Galacton chemoluminescence assay (Tropix), to correct for transfection efficiency. Unless otherwise stated, experiments were carried out in duplicate and results shown are the mean7s.e. of three independent experiments.
To determine the effect of PHB on ligand binding, COS-1 cells were grown to 80% confluence in 24-well plates in stripped media for 24 h. Cells were transfected using FuGENE 6 (Roche Diagnostics Ltd., Newhaven, UK), following the instructions provided, with 100 ng of pSVAR-WT and either 0, 10 or 100 ng of pSG5-PHB or pSG5-SRC1e. Twenty-four hours after transfection 5 nM tritiated MB (Perkin-Elmer Life Sciences) was added and cells left for 2 h at 371C. This was followed by a chase of 2 mM unlabelled MB and cells incubated at 371C for different time points. Following this, wells were washed 3 Â with PBS and shaken for 1 h at room temperature in 0.5 ml of ethanol. Samples were then transferred to scintillation vials, 3 ml of scintillation fluid (Hyonic Fluor, Beckman Coulter Ltd) added and the samples read on a scintillation counter (Beckman Coulter Ltd., Buckinghamshire, UK). Data are given as a natural logarithmic (ln) ratio of 3 H-MB bound (B) and that bound at 0 min (Bo).
Depletion of PHB by siRNA and PSA assay LNCaP cells were seeded in 96-well plates and transfected with the siRNA oligonucleotide to PHB or control random oligonucleotide as described previously . Cells were subsequently incubated for 48 h and the medium harvested. PSA levels in the media were determined using the Architect chemiluminescence total PSA immunoassay kit (Abbott Limited, Maidenhead, UK). Experiments were carried out in quadruplicate and results shown are the mean7s.e. of three independent experiments.
Generating a tetracycline-responsive cell line expressing PHB The T-REX system (Invitrogen, Paisley, UK) was used according to manufacturer's instructions to generate LNCaP cell lines that inducibly express PHB. LNCaP cell lines expressing the Tet repressor were generated by transfection with pcDNA6/TR expression plasmid and selection with resistance to 12 mg/ml blasticidin (Invitrogen). Colonies were expanded and doxycycline inducibility was estimated by luciferase assay after transient transfection with pcDNA4/ TO-luc. A subclone was chosen, designated LNCaP/ TR2, showing highly inducible and non-leaky expression of luciferase.
The tetracycline-inducible PHB expression vector pcDNA4/ TO/PHB was generated by amplifying PHB full-length coding sequence from complementary DNA (cDNA) using primers 5 0 -gca gaattc acc atg gct gcc aaa gtg ttt gag tcc att ggc-3 0 and 5 0 -acg ctcgag tca ctg ggg cag ctg gag gag cac gga ct-3 0 . PCR was carried out for 30 cycles of 951C for 30 s, 601C for 60 s and 721C for 2 min using Pfu turbo (Promega, Southampton, UK). The PCR product was cloned into the EcoR1/Xho1 sites of pcDNA4 TO (Invitrogen) and verified by sequencing. LNCaP/ TR2 cells were transfected with pcDNA4/TO/PHB using FuGENE 6, following the manufacturer's protocol. Cells were allowed to grow for 24 h and then 0.3 mg/ml zeocin (Invitrogen) added to select for stable clones. After 2-3 weeks of selection, single colonies were lifted using cloning cylinders and cell lines later expanded from these.
Semiquantitative reverse transcriptase-PCR Total RNA samples were prepared using Qiashredder and RNeasy kits (Qiagen Ltd., Crawley, UK) according to the manufacturer's instructions. After extraction, RNA was treated with DNaseI (Qiagen) to eliminate genomic DNA contamination, and then eluted. The RNA was quantified by measuring the absorbance at 260 nm. One microgram of total RNA was converted to cDNA using the SuperScript FirstStrand Synthesis system (Invitrogen), using Oligo(dT) 12À18 primers for full-length cDNA or random hexamers for reverse transcriptase-PCR (RT-PCR) detection.
One microliter of the cDNA reaction was used for RT-PCR using the Ready Mix PCR Mastermix system (Abgene, Epsom, UK). A 179 bp fragment of PHB was detected using the primer pairs 5 0 -ggc tga gca aca gaa aaa gg-3 0 and 5 0 -gct ggc agg tag gtg atg tt-3 0 with 22-24 cycles of 941C for 30 s, 521C for 30 s and 701C for 1 min. PSA was detected using the primers 5 0 -agg agt tct tga ccc caa aga aac-3 0 and 5 0 -ttg cgc aca cac gtc att g-3 0 with 22 cycles of 941C for 30 s, 601C for 45 s and 701C for 45 s. Loading control PCR reactions were carried out using primers to L19 cDNA: 5 0 -gcg gaa ggg tac agc caa t-3 0 and 5 0 -gca gcc ggc gca aa-3 0 with 22 cycles of 941C for 30 s, 601C for 45 s and 701C for 45 s.
Sulphorhodamine B assay
Cell growth was measured by sulphorhodamine B assay as previously described .
Co-immunoprecipitation
For overexpression, MCF7 cells in 6-well plates were transfected with 1.5 mg of pSVAR and 6 mg of pSG5-PHB per well using FuGENE 6 (Roche Diagnostics). Incubation was continued for 36 h before harvesting, and immunoprecipitation was carried out as described below.
MCF7 cells were washed twice in ice-cold PBS before incubation for 20 min on ice in IP buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 1 mM dithiothreitol and complete protease inhibitors (Roche)) to lyse the cells. The lysates were centrifuged at 14 000 Â g for 20 min at 41C and the resulting supernatants used for immunoprecipitation with mouse primary antibodies against PHB (Neomarkers), HDAC1 (Abcam) or Rb (Abcam). Immune complexes were then captured using protein A-sepharose, and washed three times with IP buffer before releasing the proteins by boiling for 5 min in laemmli SDS loading buffer. The released proteins were separated by SDS-PAGE and immunoblotted as described above using the rabbit anti-human AR antibody (AR C19, Santa Cruz Biotechnology, CA, USA) or anti-PHB antibody.
